| Bioactivity | JAK-IN-14 is a potent and selective JAK1 inhibitor, with an IC50 of 8-fold more selective for JAK1 than JAK2 and JAK3 (Patent WO2016119700A1, compound 16)[1]. | ||||||||||||
| Name | JAK-IN-14 | ||||||||||||
| CAS | 1973485-06-1 | ||||||||||||
| Formula | C19H15FN4O | ||||||||||||
| Molar Mass | 334.35 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Jin Li, et al. Substituted imidazo [1, 2-a] pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof. WO2016119700A1. |
JAK-IN-14
CAS: 1973485-06-1 F: C19H15FN4O W: 334.35
JAK-IN-14 is a potent and selective JAK1 inhibitor, with an IC50 of 8-fold more selective for JAK1 than JAK2 and JAK3 (P
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.